To confirm that tumor-specific CD8+T cells induced by combination therapy contributed to growth suppression of distant metastatic tumors, CD8+ cells were depleted by anti-CD8/Lyt2.1 monoclonal antibody (Supplementary Figure 4A). Here, CD8A is linked to metastatic neoplasm.